Preserving functional independence in elderly patients with cancer-associated bone disease: The role of zoledronic acid

Aging Health

Volumn 5, Issue 2, 2009, Pages 151-164

  Major, Pierre P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antitumor; Bisphosphonates; Bone metastases; Elderly patients; Malignancy; Quality of life; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN K INHIBITOR; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ADVANCED CANCER; AGED; AGING; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE TUMOR; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMA; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; HEADACHE; HEALTH CARE NEED; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; JAW OSTEONECROSIS; LEG EDEMA; LETHARGY; LOW DRUG DOSE; MENTAL HEALTH; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; OSTEOLYSIS; PAIN; PATIENT COMPLIANCE; PHYSIOTHERAPY; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; URINE RETENTION; VISUAL ANALOG SCALE; VOMITING; WEAKNESS;

EID: 70249126536     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.09.8     Document Type: Article

References (101)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer. J. Clin. 58(2), 71-96 (2008).
2. Costa L, Badia X, Chow E, Lipton A, Wardley A: Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support. Care Cancer 16(8), 879-889 (2008).
3. Gridelli C: The use of bisphosphonates in elderly cancer patients. Oncologist 12(1), 62-71 (2007).
4. Kinnane N: Burden of bone disease. Eur. J. Oncol. Nurs. 11(Suppl. 2), S28-S31 (2007).
5. Reich CD: Advances in the treatment of bone metastases. Clin. J. Oncol. Nurs. 7(6), 641-646 (2003).
6. DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F: Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support. Care Cancer 15(7), 869-876 (2007).
7. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8), 1860-1867 (2007).
8. Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS: Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 13(5), 494-502 (2008).
9. Major PP, Cook RJ, Lipton A, Terpos E: Disease and treatment parameters significantly affect skeletal complications and survival in metastatic breast cancer. Program and Abstracts of the International Bone and Mineral Society Davos Workshops: Bone Biology and Therapeutics. Davos, Switzerland, 9-14 March 2008 (Abstract 97).
10. Smith MR, Cook RJ, Coleman R et al.: Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 70(2), 315-319 (2007).
11. Maxwell C, Viale PH: Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncol. Nurs. Forum 32(3), 589-603 (2005).
12. Guise TA: Bone loss and fracture risk associated with cancer therapy. Oncologist 11(10), 1121-1131 (2006).
13. Wheeler DL, Vander Griend RA, Wronski TJ, Miller GJ, Keith EE, Graves JE: The short- and long-term effects of methotrexate on the rat skeleton. Bone 16(2), 215-221 (1995).
14. Siris ES, Brenneman SK, Barrett-Connor E et al.: The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos. Int. 17(4), 565-574 (2006).
15. Trinkaus ME, Simmons C, Myers J, Dranitsaris G, Clemons M: Skeletal related events (SREs) in patients with bone metastases from breast cancer treated with intravenous (i.v.) bisphosphonates (BPs) in the non-trial setting. J. Clin. Oncol. 26(Suppl.), 71S (2008) (Abstract 1120).
16. Steinbuch M, Youket TE, Cohen S: Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos. Int. 15(4), 323-328 (2004).
17. Margolis DJ, Knauss J, Bilker W, Baumgarten M: Medical conditions as risk factors for pressure ulcers in an outpatient setting. Age Ageing 32(3), 259-264 (2003).
18. Schlaich C, Minne HW, Bruckner T et al.: Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos. Int. 8(3), 261-267 (1998).
19. Body J-J, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M: International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur. J. Cancer 43(5), 852-858 (2007).
20. Hastings SN, Schmader KE, Sloane RJ et al.: Quality of pharmacotherapy and outcomes for older veterans discharged from the emergency department. J. Am. Geriatr. Soc. 56(5), 875-880 (2008).
21. Lindblad CI, Hanlon JT, Gross CR et al.: Clinically important drug-disease interactions and their prevalence in older adults. Clin. Ther. 28(8), 1133-1143 (2006).
22. Juhlin T, Bjorkman S, Hoglund P: Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Eur. J. Heart Fail. 7(6), 1049-1056 (2005).
23. Gooch K, Culleton BF, Manns BJ et al.: NSAID use and progression of chronic kidney disease. Am. J. Med. 120(3), 280.E281-E287 (2007).
24. Mercadante S, Arcuri E: Pharmacological management of cancer pain in the elderly. Drugs Aging 24(9), 761-776 (2007).
25. Frey E, Levy JV: Use of opioids in the elderly - pharmacokinetic and pharmacodynamic considerations. Anasthesiol. Intensivmed. Notfallmed. Schmerzther. 39(9), 527-537 (2004).
26. Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ: The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J. Clin. 57(4), 225-241 (2007).
27. Taguchi H, Oishi K, Sakamoto S, Shingu K: Intrathecal β-methasone for cancer pain in the lower half of the body: a study of its analgesic efficacy and safety. Br. J. Anaesth. 98(3), 385-389 (2007).
28. Ruan X: Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 10(2), 357-366 (2007).
29. Davis MP, Srivastava M: Demographics, assessment and management of pain in the elderly. Drugs Aging 20(1), 23-57 (2003).
30. Serafini AN: Therapy of metastatic bone pain. J. Nucl. Med. 42(6), 895-906 (2001).
31. Lewington VJ: Bone-seeking radionuclides for therapy. J. Nucl. Med. 46(Suppl. 1), 38S-47S (2005).
32. Major P: Optimal management of metastatic bone disease. Eur. J. Oncol. Nurs. 11(Suppl. 2), S32-S37 (2007).
33. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W: The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet. Disord. 8, 97 (2007).
34. Ettinger MP, Gallagher R, MacCosbe PE: Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr. Pract. 12(5), 522-528 (2006).
35. Siris ES, Harris ST, Rosen CJ et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc. 81(8), 1013-1022 (2006).
36. Hoer A, Gol D, Gothe H, Schiffhorst G, Brandman J, Haussler B: Rates and determinants of patient persistency with oral bisphosphonates in cancer patients (Abstract 07-057). Support. Care Cancer 13, 428 (2005).
37. Okuno J, Yanagi H, Tomura S: Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur. J. Clin. Pharmacol. 57(8), 589-594 (2001).
38. Rosen MI, Beauvais JE, Rigsby MO, Salahi JT, Ryan CE, Cramer JA: Neuropsychological correlates of suboptimal adherence to metformin. J. Behav. Med. 26(4), 349-360 (2003).
39. Tassinari D, Poggi B, Nicoletti S et al.: Zoledronic acid treatment at home: safety data from an observational prospective trial. J. Palliat. Med. 10(2), 352-358 (2007).
40. Wardley A, Davidson N, Barrett-Lee P et al.: Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br. J. Cancer 92(10), 1869-1876 (2005).
41. Bonefos® tablets. Schering Health Care Limited, West Sussex, UK (2005).
42. Aredia® (pamidronate disodium for injection) for intravenous infusion. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA (2005).
43. Zometa® (zoledronic acid) for injection. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA (2008).
44. Bonadrat® (ibandronate). Roche Registration Ltd, Hertfordshire, UK (2007).
45. Lipton A, Steger GG, Figueroa J et al.: Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res. 14(20), 6690-6696 (2008).
46. Le Gall C, Bonnelye E, Clezardin P: Cathepsin K inhibitors as treatment of bone metastasis. Curr. Opin. Support. Palliat. Care 2(3), 218-222 (2008).
47. Le Gall C, Bellahcene A, Bonnelye E et al.: A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 67(20), 9894-9902 (2007).
48. Zometa® (product monograph). Novartis Pharma AG, Basel, Switzerland (2002).
49. Chen T, Berenson J, Vescio R et al.: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42(11), 1228-1236 (2002).
50. Skerjanec A, Berenson J, Hsu C et al.: The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J. Clin. Pharmacol. 43(2), 154-162 (2003).
51. Dunford JE, Kwaasi AA, Rogers MJ et al.: Structure activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem. 51(7), 2187-2195 (2008).
52. Lipton A, Cook RJ, Coleman RE et al.: Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin. Lymphoma Myeloma 7(5), 346-353 (2007).
53. Schran H, Ravera C, Skerjanec A, Boisclair M: Regular dosing of zoledronic acid maintains suppression of osteolysis in patients with malignant bone disease. Program and Abstracts of the International Bone and Mineral Society Davos Workshops: Bone Biology and Therapeutics. Davos, Switzerland, 9-14 March 2008 (Abstract 199).
54. Kohno N, Aogi K, Minami H et al.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol. 23(15), 3314-3321 (2005).
55. Saad F, Gleason DM, Murray R et al.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96(11), 879-882 (2004).
56. Rosen LS, Gordon D, Tchekmedyian NS et al.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12), 2613-2621 (2004).
57. Coleman RE: Bisphosphonates: clinical experience. Oncologist 9 (Suppl, 4), 14-27 (2004).
58. Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G: Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin. Cancer Res. 10(18 pt 2), 6397S-6403S (2004).
59. Saad F: New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat. Rev. 34(2), 183-192 (2008).
60. Dearnaley DP, Sydes MR, Mason MD et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl Cancer Inst. 95(17), 1300-1311 (2003).
61. Ernst DS, Tannock IF, Winquist EW et al.: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J. Clin. Oncol. 21(17), 3335-3342 (2003).
62. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol. 21(23), 4277-4284 (2003).
63. Lipton A, Theriault RL, Hortobagyi GN et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5), 1082-1090 (2000).
64. Body JJ, Diel IJ, Lichinitser MR et al.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14(9), 1399-1405 (2003).
65. Rosen LS, Gordon D, Kaminski M et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8), 1735-1744 (2003).
66. Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergstrom B: Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. Ann. Oncol. 18(7), 1165-1171 (2007).
67. Pavlakis N, Schmidt RL, Stockler M: Bisphosphonates for breast cancer (review). Cochrane Database Sys. Rev. (1) CD003474, 1-47 (2008).
68. Hortobagyi GN, Theriault RL, Porter L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785-1791 (1996).
69. Hortobagyi GN, Theriault RL, Lipton A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J. Clin. Oncol. 16(6), 2038-2044 (1998).
70. Rosen LS, Gordon DH, Dugan W Jr et al.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1), 36-43 (2004).
71. Vogel CL, Yanagihara RH, Wood AJ et al.: Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9(6), 687-695 (2004).
72. Wong R, Wiffen PJ: Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev. (2), CD002068 (2002).
73. Lipton A: The safety of zoledronic acid. Expert Opin. Drug Saf. 6(3), 305-313 (2007).
74. Saad F, Gleason DM, Murray R et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458-1468 (2002).
75. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J: Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med. Oncol. 24(2), 227-230 (2007).
76. Zaghloul MS, Boutros R, El-Hosieny H, A-Kader Y, el-Attar I, Nazmy M: A controlled prospective randomized placebo-controlled frialof zoledronic acid in bone metastatic bladder cancer patients. J. Clin. Oncol. 26(Suppl.), 257S (2008) (Abstract 5033).
77. Hoff AO, Toth BB, Altundag K et al.: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 23(6), 826-836 (2008).
78. McArthur HL, Estilo C, Huryn J et al.: Osteonecrosis of the jaw (ONJ) among intravenous (iv.) bisphosphonate- and/or bevacizumab-treated patients at Memorial Sloan - Kettering Cancer Center (MSKCC). J. Clin. Oncol. 26(Suppl.), 523S (2008) (Abstract 9588).
79. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G: Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 44(9), 857-869 (2008).
80. Ripamonti C, Maniezzo M, Cislaghi E et al.: Application of preventive measures minimizes the occurrence of osteonecrosis of the jaw (ONJ) in solid tumor patients with bone metastases treated with bisphosphonates (BPs): a single institution series. Breast Cancer Res. Treat. 106(Suppl.), S103 (2007) (Abstract 2056).
81. Kelsey JL, Lamster IB: Influence of musculoskeletal conditions on oral health among older adults. Am. J. Public Health 98(7), 1177-1183 (2008).
82. Weitzman R, Sauter N, Eriksen EF et al.: Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit. Rev. Oncol. Hematol. 62(2), 148-152 (2007).
83. McKeage K, Plosker GL: Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. Pharmacoeconomics 26(3), 251-268 (2008).
84. Hillner BE, Weeks JC, Desch CE, Smith TJ: Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 18(1), 72-79 (2000).
85. Reed SD, Radeva JI, Glendenning GA, Coleman RE, Schulman KA: Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am. J. Clin. Oncol. 28(1), 8-16 (2005).
86. Felix J, Andreozzi V, Soares M, Passos-Coelho J; Portuguese Group for the Study of Bone Metastases: Treatment costs of skeletal-related events (SRE) in patients with metastatic breast or prostate cancer. Eur. J. Cancer 5(4), 172-173 (2007).
87. DesHarnais Castel L, Bajwa K, Markle JP, Timbie JW, Zacker C, Schulman KA: A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support. Care Cancer 9(7), 545-551 (2001).
88. Cook RJ, Hirsh V, Major PP et al.: Meta-analysis of effects of zoledronic acid on survival in metastatic bone disease: survival in patients with high bone turnover. J. Clin. Oncol. 26(Suppl.), 729S (2008) (Abstract 20562).
89. Hirsh V, Major PP, Lipton et al.: Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J. Thorac. Oncol. 3(3), 228-236 (2008).
90. Brufsky A, Bundred N, Coleman R et al.: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13(5), 503-514 (2008).
91. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 25(7), 820-828 (2007).
92. Israeli RS, Rosenberg SJ, Saltzstein DR et al.: The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin. Genitourin. Cancer 5(4), 271-277 (2007).
93. Polascik TJ, Given RW, Metzget C et al.: Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 66(5), 1054-1059 (2005).
94. Ryan CW, Hud D, Demers LM, Beer TM, Lacerna LV: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J. Urol. 176(3). 972-978; discussion 978 (2006).
95. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 169(6), 2008-2012 (2003).
96. Gnant M, Mlineritsch B, Schippinger W et al.: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12. J. Clin. Oncol. 26(Suppl.), 6S (2008) (Abstract LBA4).
97. Santini D, Caraglia M, Vincenzi B et al.: Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat. Clin. Pract. Oncol. 3(6), 325-338 (2006).
98. Santini D, Martini F, Fratto ME et al.: In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients. Cancer Immunol. Immunother. 58(1), 31-38 (2008).
99. Santini D, Vincenzi B, Galluzzo S et al.: Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13(15 Pt 1), 4482-4486 (2007).
100. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L: Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med. Oncol. 22(2), 195-201 (2005).
101. Rack BK, Jueckstock J, Genss EM et al.: Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Program and Abstracts of the 30th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 13-16 December 2007 (Abstract 511).